(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.73%) $79.57
(5.62%) $2.31
(1.33%) $2 353.10
(3.53%) $28.58
(0.85%) $993.00
(-0.28%) $0.928
(-0.22%) $10.87
(-0.19%) $0.799
(0.89%) $92.55
Live Chart Being Loaded With Signals
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development...
Stats | |
---|---|
今日成交量 | 192 108 |
平均成交量 | 1.36M |
市值 | 4.40B |
EPS | £0 ( 2024-02-25 ) |
Last Dividend | £12.50 ( 2023-03-09 ) |
Next Dividend | £0 ( N/A ) |
P/E | -154.64 |
ATR14 | £15.19 (0.39%) |
音量 相关性
Dechra Pharmaceuticals 相关性 - 货币/商品
Dechra Pharmaceuticals 财务报表
Annual | 2022 |
营收: | £761.50M |
毛利润: | £426.30M (55.98 %) |
EPS: | £-0.240 |
FY | 2022 |
营收: | £761.50M |
毛利润: | £426.30M (55.98 %) |
EPS: | £-0.240 |
FY | 2022 |
营收: | £681.80M |
毛利润: | £384.80M (56.44 %) |
EPS: | £0.540 |
FY | 2021 |
营收: | £608.00M |
毛利润: | £345.90M (56.89 %) |
EPS: | £0.538 |
Financial Reports:
No articles found.
Dechra Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£32.89 (N/A) |
£12.50 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £1.133 | 2001-03-07 |
Last Dividend | £12.50 | 2023-03-09 |
Next Dividend | £0 | N/A |
Payout Date | 2023-04-13 | |
Next Payout Date | N/A | |
# dividends | 45 | -- |
Total Paid Out | £356.25 | -- |
Avg. Dividend % Per Year | 0.54% | -- |
Score | 2.05 | -- |
Div. Sustainability Score | 3.80 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 1.261 | -- |
Year | Amount | Yield |
---|---|---|
2001 | £0 | 0.00% |
2002 | £0 | 0.00% |
2003 | £0 | 0.00% |
2004 | £0 | 0.00% |
2005 | £0 | 0.00% |
2006 | £0 | 0.00% |
2007 | £0 | 0.00% |
2008 | £0 | 0.00% |
2009 | £0 | 0.00% |
2010 | £0 | 0.00% |
2011 | £0 | 0.00% |
2012 | £0 | 0.00% |
2013 | £0 | 0.00% |
2014 | £0 | 0.00% |
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £25.50 | 0.92% |
2019 | £31.60 | 1.51% |
2020 | £34.29 | 1.17% |
2021 | £40.50 | 1.14% |
2022 | £44.89 | 0.94% |
2023 | £12.50 | 0.48% |
2024 | £0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
WEIR.L | Dividend Knight | 2023-10-05 | Annually | 32 | 0.80% | |
MUL.L | Ex Dividend Junior | 2023-10-26 | Sporadic | 29 | 0.20% | |
DSW.L | Dividend Junior | 2023-09-14 | Semi-Annually | 3 | 0.01% | |
SMWH.L | Dividend Knight | 2023-07-13 | Annually | 18 | 0.41% | |
INSE.L | Dividend Junior | 2023-10-12 | Annually | 12 | 0.60% | |
BPT.L | Dividend Knight | 2023-08-17 | Semi-Annually | 3 | 1.74% | |
PAGE.L | Dividend Knight | 2023-08-31 | Annually | 24 | 3.53% | |
FEN.L | Ex Dividend Knight | 2023-10-05 | Annually | 13 | 1.04% | |
TATE.L | Dividend King | 2023-06-22 | Semi-Annually | 33 | 4.49% | |
KITW.L | Dividend Knight | 2023-07-13 | Semi-Annually | 4 | 2.78% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0366 | 1.500 | -0.733 | -1.099 | [0 - 0.5] |
returnOnAssetsTTM | -0.0178 | 1.200 | -0.593 | -0.711 | [0 - 0.3] |
returnOnEquityTTM | -0.0349 | 1.500 | -1.499 | -2.25 | [0.1 - 1] |
payoutRatioTTM | -1.853 | -1.000 | -10.00 | 10.00 | [0 - 1] |
currentRatioTTM | 2.85 | 0.800 | 0.735 | 0.588 | [1 - 3] |
quickRatioTTM | 1.333 | 0.800 | 6.87 | 5.49 | [0.8 - 2.5] |
cashRatioTTM | 0.454 | 1.500 | 8.59 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.321 | -1.500 | 4.64 | -6.96 | [0 - 0.6] |
interestCoverageTTM | 0.767 | 1.000 | -0.827 | -0.827 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.559 | 2.00 | 9.81 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.358 | 2.00 | 9.82 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.668 | -1.500 | 7.33 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.564 | 1.000 | 3.93 | 3.93 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0225 | 1.000 | -1.551 | -1.551 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.126 | 1.000 | -0.411 | -0.411 | [0.2 - 2] |
assetTurnoverTTM | 0.485 | 0.800 | -0.0986 | -0.0788 | [0.5 - 2] |
Total Score | 3.80 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -157.77 | 1.000 | -10.00 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0349 | 2.50 | -0.964 | -2.25 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.358 | 2.00 | 9.88 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.559 | 2.00 | 9.81 | 10.00 | [0 - 30] |
payoutRatioTTM | -1.853 | 1.500 | -10.00 | 10.00 | [0 - 1] |
pegRatioTTM | -2 682.07 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0835 | 1.000 | -0.412 | 0 | [0.1 - 0.5] |
Total Score | -1.282 |
Dechra Pharmaceuticals
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。